GeorgiaTuberculosis profile
Population  2014 4 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.27 (0.2–0.34) 6.6 (5.1–8.3)
Mortality (HIV+TB only) 0.017 (0.01–0.025) 0.42 (0.26–0.63)
Prevalence  (includes HIV+TB) 5.9 (2.8–10) 145 (70–248)
Incidence  (includes HIV+TB) 4.3 (4–4.6) 106 (99–114)
Incidence (HIV+TB only) 0.16 (0.13–0.19) 3.9 (3.2–4.8)
         
Case detection, all forms (%) 75 (70–80)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 12 (10–13) 39 (35–44)
MDR-TB cases among notified pulmonary
TB cases
250 (220–290) 390 (350–440)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 797   306
Pulmonary, clinically diagnosed 349   44
Extrapulmonary 661   43
       
Total new and relapse 3 200    
Previously treated, excluding relapses 650    
Total cases notified 3 850    
Among 3 200 new and relapse cases:
129 (4%) cases aged under 15 years; male:female ratio: 2.0
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 700 (95%) 634 (61%) 2 334
Laboratory-confirmed RR-/MDR-TB cases     441
Patients started on MDR-TB treatment ***     501
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 591 (67)
HIV-positive TB patients 57 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 56 (98)
HIV-positive TB patients on antiretroviral therapy (ART) 56 (98)
HIV-positive people screened for TB 2 732  
HIV-positive people provided with IPT 106  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (80) 3 098
Previously treated cases, excluding relapse, registered in 2013 (69) 779
HIV-positive TB cases, all types, registered in 2013 (68) 31
RR-/MDR-TB cases started on second-line treatment in 2012 (48) 623
XDR-TB cases started on second-line treatment in 2012 (28) 43
Laboratories 2014  
Smear (per 100 000 population) 0.3
Culture (per 5 million population) 2.5
Drug susceptibility testing (per 5 million population) 1.2
Sites performing Xpert MTB/RIF 11
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 17
% Funded domestically 33%
% Funded internationally 48%
% Unfunded 19%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-24 Data: www.who.int/tb/data